Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
7,779 results
- Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: Complete Statistical AnalysisIndependent statistical analysis of Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04853238).
- Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach: Complete Statistical AnalysisIndependent statistical analysis of Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03322358).
- CHRONICLEIndependent statistical analysis of A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Chronotropic Incompetence in Patients With HFpEF: Complete Statistical AnalysisIndependent statistical analysis of Chronotropic Incompetence in Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02524145).
- Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM): Complete Statistical AnalysisIndependent statistical analysis of Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cigarette Pack Inserts for Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Cigarette Pack Inserts for Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04075682).
- Cigarillo Warnings Image Sorting Study: Complete Statistical AnalysisIndependent statistical analysis of Cigarillo Warnings Image Sorting Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05838378).
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): Complete Statistical AnalysisIndependent statistical analysis of Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00093964).
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CiloMecTIndependent statistical analysis of Pharmacodynamic Study of Cilostazol in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02554721).
- Cilostazol 50 mg Tablets Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Cilostazol 50 mg Tablets Under Fasting Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00839930).
- Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): Complete Statistical AnalysisIndependent statistical analysis of Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01483118).
- CINTIndependent statistical analysis of PC-Based Rehabilitation of Auditory Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00724347).
- Circadian Brown Adipose Tissue Metabolism: Complete Statistical AnalysisIndependent statistical analysis of Circadian Brown Adipose Tissue Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02285270).
- Circadian Effects of Escitalopram: Complete Statistical AnalysisIndependent statistical analysis of Circadian Effects of Escitalopram: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01214044).
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: Complete Statistical AnalysisIndependent statistical analysis of Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CIRTIndependent statistical analysis of Cardiovascular Inflammation Reduction Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594333).
- Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Citicoline in Non-Arteritic Ischemic Optic Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Citicoline in Non-Arteritic Ischemic Optic Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03758118).
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01026623).
- CJC-TraCIndependent statistical analysis of Criminal Justice Coordinated Transitional Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05376371).
- CL01-TIndependent statistical analysis of A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously: primary endpoint results, effect…
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CLANIndependent statistical analysis of Contact Lens Adaptation in Neophytes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02148263).
- Clareon PanOptix Pro vs. Clareon PanOptix – Study A: Complete Statistical AnalysisIndependent statistical analysis of Clareon PanOptix Pro vs. Clareon PanOptix - Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06400745).
- Clareon Toric vs Eyhance Toric: Complete Statistical AnalysisIndependent statistical analysis of Clareon Toric vs Eyhance Toric: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05481125).
- Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00840411).
- Clarithromycin for the Treatment of Hypersomnia: Complete Statistical AnalysisIndependent statistical analysis of Clarithromycin for the Treatment of Hypersomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01146600).
- CLARITYIndependent statistical analysis of A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CLASSICIIIndependent statistical analysis of Remission in Subjects With Crohn's Disease, 1 Year Phase: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00055497).
- Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant: Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03380962).
- CLBP Single-Arm Long-Term Follow-up Study: Complete Statistical AnalysisIndependent statistical analysis of CLBP Single-Arm Long-Term Follow-up Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05207813).
- Cleaner Air for Better Cardiac Biomarkers: Complete Statistical AnalysisIndependent statistical analysis of Cleaner Air for Better Cardiac Biomarkers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05379400).
- Cleansing Device for the Treatment of Scalp and Hair Conditions: Complete Statistical AnalysisIndependent statistical analysis of Cleansing Device for the Treatment of Scalp and Hair Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05319444).
- CLEARIndependent statistical analysis of Cilostazol After Lower Extremity Arterial Revascularization Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02374957).
- CLEARIndependent statistical analysis of Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CLEAR 2Independent statistical analysis of Combining Lesinurad With Allopurinol in Inadequate Responders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01493531).
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…
- CLEARANCEIndependent statistical analysis of CLinical Evaluation of Aspiration for Removal ANd ClearancE of Stones: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06615713).
- ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users: Complete Statistical AnalysisIndependent statistical analysis of ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01066780).
- Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04245709).
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.